Tianjin Pharmacn Medical Technology Co., Ltd.

  • 2023 CPHI Shanghai Fair
  • 2023 CPHI Shanghai Fair
  • 2023 CPHI Shanghai Fair
  • 2023 CPHI Shanghai Fair
  • 2023 CPHI Shanghai Fair
About Tianjin Pharmacn Medical Technology Co., Ltd.

Tianjin Pharmacn Medical Technology Co., Ltd is a high-tech enterprise, integrating the R&D, manufacturing and marketing of active pharmaceutical ingredients (APIs) and intermediates. It has R&D center,optimization and industrial preparation pilot workshops. Focusing on the R & D and manufacturing of advanced pharmaceutical raw materials and intermediates, especially in the field of anti-tumor, diabetes and cardiovascular intermediates. At the same time, the company can also provide impurity tracking, stability analysis and CTD documentation and other technical services.  Tianjin Pharmacn is equipped with more than 100 sets of 100L-5000L reactor, the annual manufacturing capacity is 500 tons. It can realize high and low temperature reaction at -100-240℃, various catalytic reactions and anhydrous and anaerobic reactions at 0~5MPa, and has the leading technical capability in the synthesis of heterocyclic compounds. Tianjin Pharmacn owns an experienced quality management team which has established perfect quality standard system and carried out whole-process supervision and management from risk assessment, product research and development, the enterprise transfer...

Certifications
  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Intermediates Manufacturer
Contact info

Products from Tianjin Pharmacn Medical Technology Co., Ltd. (100)

  • Palbociclib Series

    Product Palbociclib Series

    Palbociclib is a Kinase Inhibitor. The mechanism of action of palbociclib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor.
  • Ribociclib Series

    Product Ribociclib Series

    a cyclin-dependent kinase (CDK) inhibitor that targets cyclin D1/CDK4 and cyclin D3/CDK6 at nanomolar concentrations. It inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiti...
  • Cabozantinib Series

    Product Cabozantinib Series

    Cabozantinib was approved in November 2012 for the treatment of patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Cabozantinib was granted orphan drug status by the FDA to facilitate development of newtreatment options for patients with MTC. It is a me...
  • Iguratimod Series

    Product Iguratimod Series

    Iguratimod is a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced ar...
  • Dexmedetomidine hydrochloride Series

    Product Dexmedetomidine hydrochloride Series

    Dexmedetomidine was launched in the US as an i.v. infusion for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care unit, This imidazole derivative is the (S)-enantiomer of medetomidine that can be obtained via fractional crystallization of the tartrate...
  • Fluorometholone Series

    Product Fluorometholone Series

    Fluorometholone is the topical synthetic glucocorticoid. Its tropical anti-inflammatory effect is 40 times as much as hydrocortisone, but their effects of oral administration are almost equal. It is mainly used for local treatment of skin allergy, pruritus, rash and other diseases related to allergy. Oral ...
  • Linezolid Series

    Product Linezolid Series

    Linezolid is for the treatment of patients with infections caused by serious Gram-positive pathogens, particularly skin and soft tissue infections, communityacquired pneumonia and vancomycin-resistant enterococcal infections. Linezolid is the (S)-enantiomer of an oxazolidin-2-one synthesized in a multistep...
  • Cisatracurium Besylate Series

    Product Cisatracurium Besylate Series

    Cisatracurium besylate is a new intermediate-duration non-depolarizing muscle relaxant launched in the U.S.A. for intubation and maintenance of muscle relaxation during surgery and intensive care. Cisatracurium besylate is the single 1 R cis-1'R cis isomer of the commercial preparation of atracurium, a mix...
  • 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one

    Product 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals . Contact us for more information.
  • N-(4-(2-aminoacetyl)-5-methoxy-2-phenoxyphenyl)methanesulfonamide hydrochloride

    Product N-(4-(2-aminoacetyl)-5-methoxy-2-phenoxyphenyl)methanesulfonamide hydrochloride

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals . Contact us for more information.
  • MethanesulfonaMide, N-[4-[2-(forMylaMino)acetyl]-5-hydroxy-2-phenoxyphenyl]-

    Product MethanesulfonaMide, N-[4-[2-(forMylaMino)acetyl]-5-hydroxy-2-phenoxyphenyl]-

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals . Contact us for more information.

Tianjin Pharmacn Medical Technology Co., Ltd. Resources (2)

  • Brochure Product Brochure

    Tianjin pharmacn medical technology co ltd offers Apis, pharmaceutical intermediates and fine chemicals. Contact us for more information.
  • Video 2023 CPHI Shanghai Fair

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals. Contact us for more information.